Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 13/20 | 0.59 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.59 |
| ▸ | TNF | P01375 | 3/20 | 0.59 |
| ▸ | IL1B | P01584 | 3/20 | 0.59 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18712198 | 1.00 | CRBN (0.59) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21207999 | 0.88 | CRBN (0.58) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL24712763 | 0.86 | CRBN (0.47) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL19387907 | 0.86 | CRBN (0.59) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21107417 | 0.85 | CRBN (0.58) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21896472 | 0.83 | CRBN (0.47) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL22606726 | 0.82 | CRBN (0.47) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL23142992 | 0.82 | CRBN (0.44) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL22566731 | 0.82 | CRBN (0.44) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL20759891 | 0.82 | CRBN (0.44) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022111526-A1 | BENZENE RING DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2022-06-02 | — | — | WO | disclosed |
| WO-2021022076-A1 | MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2021-02-04 | — | — | WO | disclosed |
| US-10829472-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200140408-A1 | CRYSTALLINE 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE HEMIHYDRATE, COMPOSITIONS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2020-05-07 | — | — | US | disclosed |
| EP-3076973-B1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS | ACETYLON PHARMACEUTICALS INC (US) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829472-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof | QDPR, HTR3D, IAPP | CRBN 3178/4885DDB1 1657/4885IKZF3 3275/4885 |
| US-20200140408-A1 | CRYSTALLINE 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE HEMIHYDRATE, COMPOSITIONS AND METHODS OF USE THEREOF | QDPR, HTR3D, IAPP | CRBN 3178/4885DDB1 1657/4885IKZF3 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.